BriaCell Therapeutics’ (TSXV:BCT; OTCQB:BCTXF) clinical findings will be published in the 2019 American Society of Clinical Oncology (ASCO) annual meeting proceedings, a supplement to the Journal of Clinical Oncology. The ASCO meeting is May 31 to June 4 in Chicago.
In addition, Dr. Bill Williams, BriaCell’s president and CEO, will be presenting at the Precision Breast Cancer Conference on April 24 and 25 in Boston.
“Our clinical data elucidates novel ways to fight cancer, and solidifies our unique and simple HLA (human leukocyte antigen) profiling approach, which provides a precise personalized treatment option for advanced breast cancer patients,” Dr. Williams said in a statement.
“We are also thrilled with the prospects of our previously-reported additive or synergistic anti-tumor activity of Bria-IMT, in combination with KEYTRUDA, offering potential clinical benefit to advanced breast cancer patients, and look forward to sharing additional data in the second half of 2019,” he added.
BriaCell is currently conducting a Phase 1/2a clinical trial of Bria-IMT in combination with KEYTRUDA.
